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Background: Itch, chronic itch in particular, can have a significant negative impact on an individual’s quality of life.
However, the molecular mechanisms underlying itch processing in the central nervous system remain largely
unknown.
Results: We report here that activation of ERK signaling in the spinal cord is required for itch sensation. ERK
activation, as revealed by anti-phosphorylated ERK1/2 immunostaining, is observed in the spinal dorsal horn of
mice treated with intradermal injections of histamine and compound 48/80 but not chloroquine or SLIGRL-NH2,
indicating that ERK activation only occurs in histamine-dependent acute itch. In addition, ERK activation is also
observed in 2, 4-dinitrofluorobenzene (DNFB)-induced itch. Consistently, intrathecal administration of the ERK
phosphorylation inhibitor U0126 dramatically reduces the scratching behaviors induced by histamine and DNFB,
but not by chloroquine. Furthermore, administration of the histamine receptor H1 antagonist chlorpheniramine
decreases the scratching behaviors and ERK activation induced by histamine, but has no effect on DNFB-induced
itch responses. Finally, the patch-clamp recording shows that in histamine-, chloroquine- and DNFB-treated mice
the spontaneous excitatory postsynaptic current (sEPSC) of dorsal horn neurons is increased, and the decrease of
action potential threshold is largely prevented by bathing of U0126 in histamine- and DNFB-treated mice but not
those treated with chloroquine.
Conclusion: Our results demonstrate a critical role for ERK activation in itch sensation at the spinal level.
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Itching is an unpleasant cutaneous sensation that pro-
vokes the desire or reflex to scratch. The sensation of
itch can be divided into acute and chronic categories, ac-
cording to its persistence period [1,2]. Acute itch, much
like acute pain, serves as a physiological, self-protective
warning signal that helps prevent the body from being
hurt. Chronic itch, however, is a common symptom of
many serious dermatological illnesses, as well as diseases
affecting other body systems. In the case of chronic itch,* Correspondence: lzhang0808@tongji.edu.cn; dingyuqiang@gmail.com
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unless otherwise stated.anti-histamines are usually not an effective clinical treat-
ment [3,4]. A better understanding of the cellular and
molecular mechanisms that underlie different itching
sensations and their processing is urgently needed in or-
der to develop new itch relief methods.
In the last five years, huge progress has been made to-
wards elucidating the mechanisms underlying itch devel-
opment at the spinal level. In particular, gastrin releasing
peptide receptor (GRPR)-expressing neurons in the spinal
dorsal horn have been found to mediate both histamine-
dependent and -independent acute itch, but are not
involved in pain processing [5,6]. Moreover, the G-protein-
coupled receptor MrgprA3 was shown to mediate the itch
response induced by chloroquine, an anti-malarial drug
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transcription factor Bhlhb5 in the spinal cord display en-
hanced spontaneous scratching behaviors, but their pain
behaviors remain unchanged [8]. Toll-like receptor 3 and
7, the family members that mediate innate immunity, are
important for the development of itch and spinal synaptic
transmission [9,10]. Furthermore, mice in which vesicle
glutamate transporter type 2 expression has been spe-
cifically deleted from Nav1.8-expressing primary sen-
sory neurons in the dorsal root ganglia (DRG) exhibit
not only decreased glutamate release in the spinal dorsal
horn, but also decreased pain sensation and enhanced itch
responses [11].
Extracellular signal-regulated kinases ERK1/2, two
closely related members of the mitogen-activated pro-
tein kinase family, transduce extracellular stimuli into
intracellular signaling through various transcriptional
and post-translational mechanisms [12]. Accumulating
evidence has shown that noxious peripheral stimula-
tion promotes the phosphorylation of ERK1/2 (pERK)
in the spinal dorsal horn, and that ERK1/2 activation
is important for the development of inflammatory and
neuropathic pain via the enhancement of synaptic plasti-
city in the spinal cord [13-15]. Pain and itch are the two
major somatosensations, which are transmitted by pri-
mary sensory neurons in the DRG, processed in the spinalFigure 1 Time-dependent induction of pERK expression by histamine
obvious increase in the number of pERK-positive cells is observed at 2 min
sustained until 60 min (C, E), and a marked decline is seen at 90 min post-
fasciculus; lf, lateral fasciculus. Scale bar, 100 μm.dorsal horn first and then conveyed by the second-order
neurons in the spinal dorsal horn to the supraspinal sites
for the generation of individual perception [16,17]. Given
that pain and itch have much in common, in the present
study, we set out to explore whether ERK activation is in-
volved in processing itch-related signals in the spinal cord.
Results
Spinal ERK signaling is activated in histamine- but not
chloroquine-induced acute itch
Histamine and chloroquine were used to induce
histamine- and non-histamine-dependent acute itch,
respectively [5]. Consistent with previous reports [5,7,9],
intradermal injections of histamine into the nape elicited
vigorous scratching with the hind paws within the first
30 min (201.60 ± 39.69/30 min). Scratching decreased
greatly after this time point, and thus behavioral data from
the first 30 min post-injection were used for comparison.
Since pERK is an indicator of ERK activation [13,18,19],
we examined its expression in the spinal cord at vari-
ous time points after histamine injection. The number
of pERK-expressing cells was obviously increased as
of 5 min post-injection, peaked at 30 min, maintained
peak levels until 60 min, then decreased dramatically
at 90 min relative to controls received PBS injection
(Figures 1 and 2A, G). In addition, pERK-positive cells. (A) Few pERK-positive cells are seen in PBS-injected mice. (B-E) An
post-histamine injection (B, E), peak levels are achieved at 30 min and
injection (D, E). n = 6 for each time point. DH, dorsal horn; df, dorsal
Figure 2 Expression of pERK and c-Fos in the spinal dorsal horn 30 min after injection of histamine, compound 48/80, chloroquine or
SLIGRL-NH2. (A-D) pERK is expressed in the lateral dorsal horn of mice injected with histamine and compound 48/80 (A, C) but not with
chloroquine and SLIGRL-NH2 (B, D) in the nape. (E, F) Similar c-Fos expression is observed in the dorsal horn after injection of chloroquine or
histamine in the nape. (G) Comparison of the number of pERK-positive cells in the dorsal horn of mice treated with PBS, histamine and chloroquine.
One way ANOVA; P < 0.001; **P < 0.01; n = 5 for each group. (H) Comparison of the number of c-Fos-positive cells in the dorsal horn of mice treated
with chloroquine or histamine as shown in (E, F). Student’s t-test; P > 0.05; n = 5 for each group. (I) pERK is expressed in the medial dorsal horn of
mice that received histamine injection in a hind paw. (J) pERK-positive cells are distributed in the dorsal part of the medullary dorsal horn of mice with
histamine injection in the cheek region. DH, dorsal horn; df, dorsal fasciculus; lf, lateral fasciculus; MDH, medullary dorsal horn; t, spinal trigeminal tract.
Scale bars, 100 μm in F (applies to A-F and I) and 200 μm in J.
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scratch, showing that the ERK activation is caused by his-
tamine rather than scratching itself. Taken together, these
results demonstrate that injection of histamine leads to
ERK activation in the spinal cord.
Consistent with previously reported findings [5-7],
chloroquine also induced vigorous scratching responses
(220.16 ± 35.75/30 min), but did not lead to an obvious
increase of pERK expression in the spinal cord at any of
the time points examined (one way ANOVA, P > 0.05),
as compared with mice injected with PBS (Figures 1A
and 2B, G). Therefore, ERK signaling in the spinal cord
is specifically activated in histamine-induced, but not
chloroquine-induced acute itch.To further confirm the specific activation of ERK sig-
naling in histamine-induced itch, we tested two other
substances: compound 48/80, a histamine-dependent pru-
ritogen, and SLIGRL-NH2, a proteinase-activated receptor
2 agonist that induces histamine-independent acute itch
[5,6]. Our results showed that compound 48/80 dramatic-
ally increased ERK activation in the spinal dorsal horn,
whereas SLIGRL-NH2 did not do so (Figure 2C, D).
The proto-oncogene c-Fos is an indicator of neuronal
activation in the central nervous system [20]. Obvious
increases in the numbers of c-Fos-positive neurons were
seen in the spinal dorsal horn 30 min after injection of
histamine and chloroquine (Figure 2E, F). It should be
noted that there were no significant differences between
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c-Fos-positive cells (Figure 2E, F, H). Thus, the observed
lack of pERK expression in chloroquine-treated mice is
not due to any inability of the spinal neurons to respond
to peripheral itch-related sensory inputs.
We next examined the distribution patterns of ERK
activation in the spinal cord. Intradermal injections of his-
tamine into the nape led to pERK expression in the lateral
part of the bilateral cervical dorsal horns (Figure 2A), and
intradermal injections of histamine into a single hind paw
resulted in pERK activation in the medial part of the ipsi-
lateral dorsal horn in the lumbar segments (Figure 2I).
This topographical pattern of pERK activation in the spi-
nal dorsal horn is consistent with the topographical ter-
mination sites of primary sensory axons from the bodyFigure 3 Dose-dependent induction of pERK expression and scratchin
histamine into the nape region, the number of pERK-positive cells in the sp
increased compared with those treated with 50 μg or 250 μg (A), and the
increased as the histamine dosage increased from 50 μg, to 250 μg to 500
numbers and ERK activation are highly correlated in the dose range from 5
and 500 μg groups and n = 4 for 250 μg group. (C, D, F) Thirty min post-in
medullary dorsal horn (C) and scratches are increased in number in dose-d
One way ANOVA; P < 0.001; n = 7 for PBS and 10 μg groups, n = 10 for 20 μ
with no obvious change. One way ANOVA; P > 0.05. Regression analysis of nu
analysis; R2 = 0.95, P < 0.01; n = 4 for PBS, 10 μg and 50 μg groups and n = 6 fo[21], thus further suggesting that ERK activation is
specifically induced by histamine-related peripheral itch
stimuli.
To determine whether histamine-mediated ERK ac-
tivation is dose dependent, we tested the effect of two
lower doses of histamine (50 μg and 250 μg) in addition
to the original dose of 500 μg. Treated mice were then
sacrificed after 30-min behavioral observation and proc-
essed for pERK immunostaining. The results showed
that lower doses of histamine also elicited scratching re-
sponses (Figure 3B) and pERK activation (Figure 3A),
but to a significantly lesser degree than the 500 μg dose
(Figure 3A, B). The scratch numbers and ERK activation
induced by histamine were highly correlated in dose
range (50–500 μg) used, as shown in Figure 3E. Theseg response by histamine. (A, B, E) Thirty min after injection of
inal cord of mice treated with 500 μg of histamine was significantly
number of scratches recorded in the first 30 min post-injection
μg (B). One way ANOVA; P < 0.001; n = 6 for each group. The scratch
0 to 500 μg (E). Regression analysis; R2 = 0.86; P < 0.01; n = 5 for 50 μg
jection of histamine into the cheek region, pERK-positive cells in the
ependent manner as the doses increased from 10 μg to 50 μg (D).
g and 50 μg groups. Wiping number is maintained at a very low level
mbers of pERK-positive cells and scratches is shown in (F). Regression
r 20 μg group. *P < 0.05; **P < 0.01.
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ing by histamine is dose dependent.
ERK signaling is also activated in histamine-induced itch
cheek model
The itch cheek model can differentiate the behavior of
itch and pain in mice, because histamine mainly elicits
itch response shown by scratching with hind limb, while
capsaicin evokes nociceptive response shown by wiping
with the forelimb [22,23]. To further confirm the conclu-
sion that ERK signals is activated by histamine-induced
itch, histamine (10–50 μg in 10 μl PBS) was injected into
the cheek region, and the behaviors of scratching and wip-
ing were measured in 30 min after the injection. Hista-
mine evoked vigorous scratching directed to the injection
site, and scratching number was increased as the dose of
histamine increased from 10 μg to 50 μg (Figure 3D). Al-
though a small amount of wiping responses were ob-
served, it did not have significant difference compared
with PBS control or among groups treated with different
doses of histamine (Figure 3D), which is in line with
the previous report [23]. After the behavioral observa-
tion, the mice were sacrificed immediately and proc-
essed for pERK immunostaining as mentioned above.
Many pERK-positive cells were observed in the super-
ficial layers of the medullary dorsal horn in histamine-
treated mice (Figure 2J), whereas only a few were found
in controls injected with PBS. A significant difference
was observed in pERK-positive cell number between
histamine-injected and control mice as well as between
histamine-injected mice with different doses (Figure 3C).
Moreover, the increase of number of pERK-positive cells
was highly correlated with the scratching response
(Figure 3F). Thus, ERK activation is also present in
histamine-induced itch cheek model. It should be noted
that lower dose of histamine (e.g. 50 μg) could elicit
robust scratches in itch cheek model but it only in-
duced a small amount of scratches in itch nape model
(Figure 3B, D). This may reflect the possibility that the
orofacial region is more sensitive to histamine-induced
itch possibly caused by a higher density of peripheral
nerve innervation compared with the nape area.
ERK signaling is activated in DNFB-induced itch
Consistent with the published report [24], repeat appli-
cations of DNFB to the skin of the nape resulted in
scratching behaviors as well as lesions on the treated
area (Figure 4A, B). Histological examination of DNFB-
treated samples revealed a number of pathological alter-
ations typical of atopic dermatitis, including irregular
hyperplasia, enhanced staining of eosinophilic fibers and
variable numbers of inflammatory cells (Figure 4C, D).
We next set out to establish whether ERK is also acti-
vated in the spinal cord in response to DNFB-induceditch. We observed a number of pERK-positive cells in
the spinal cord of the treated mice (25.5 ± 1.58/section),
whereas only a few positive cells were seen in control
mice treated with acetone alone (1.6 ± 0.26/section;
Figure 4E, F) 30 min after the last painting of DNFB.
A significant difference in cell number between the two
treatments was observed (n = 6 for each; Student t-test,
P < 0.01). , showing that spinal ERK signaling is acti-
vated in DNFB-induced itch.
The scratching behavior was dramatically increased in
the first 30 min in the DNFB-treated mice (Figure 4G).
However, repeated-DNFB painting may lead to the acute
allergic responses by DNFB, which contributes to the in-
creased scratching behavior. To address this issue, we
performed a control experiment in which mice painted
with 3 times of acetone first and one time of DNFB last
were included. These mice also showed vigorous scrat-
ching in the first 2 h, but it was largely attenuated in
the second 2 h and disappeared in the third 2 h after
the last painting DNFB (Figure 4H), suggesting that
DNFB-elicited scratching is not due to an acute aller-
gic response. Although there was no significant diffe-
rence in scratching number in the first 2 h between
the control mice and repeatedly DNFB-painted mice,
the latter still showed a high level of scratching re-
sponse in the second and third 2 h and even 1 week
after the last DNFB painting (Figure 4H). Considering
the appearance of typical pathological alterations of atopic
dermatitis and long-lasting scratching behaviors, the
repeated-DNFB painting protocol could be used to induce
chronic itch.ERK activation is specifically localized to spinal neurons
but not glia
To further characterize the distribution of pERK in the
spinal dorsal horn, we performed co-immunostaining of
pERK and PKCγ, the latter of which is enriched in the
inner lamina II [25]. We found that the vast majority of
pERK-positive cells (120/134) were located dorsally to
PKCγ-positive cells (Figure 5A, B), indicating that pERK
expression is primarily localized in layer I and outer
lamina II. To determine whether pERK is expressed in
neurons or in glia, we co-immunostained pERK toge-
ther with NeuN, GFAP or OX-42, which are specific
makers for neuron, astrocyte and microglia, respect-
ively. Thirty min after histamine injection, almost all
pERK-expressing cells (180/195) were also positive for
NeuN, but none of them were co-stained with GFAP
(0/180) or OX-42 (0/190) antibody (Figure 5C-E). Similar
results were obtained in DNFB-treated mice (Figure 5F-H).
Taken together, these findings suggest that histamine- and
DNFB-induced ERK activation occurs in spinal neurons,
but not glia.
Figure 4 pERK expression and scratches in DNFB-painted mice. (A, B) Severe skin lesions are seen in mice treated with repeated DNFB
painting (B), but not in control mice with repeated acetone painting (A). (C, D) Hematoxylin/eosin staining reveals irregular hyperplasia
(triangles), enhanced staining of eosinophilic fibers and variable numbers of inflammatory cells (arrows) in the dermis of DNFB-treated skin
samples (D), but not in those treated with acetone alone (C). (E, F) pERK is expressed in the dorsal horn of mice treated repeatedly with DNFB
(F), but not with acetone (E). Comparison of scratches in 30 min between the two groups is shown in (G). Student’s t-test; **P < 0.01; n = 5 for
each group. The upper diagram indicates the detailed procedure for DNFB painting, behavior observation and immunostaining conducted in
(A-G). (H) Comparison of scratching number between the mice treated with 4 times of DNFB and those treated with 3 time of acetone and one
time of DNFB. Significant differences are not seen in the first 2 h, but are present in the second and third 2 h as well as one week later. Two way
repeated ANOVA; P < 0.01; One way ANOVA for comparison at individual time points; **P < 0.01; n = 5 for each group. The diagram shows the
detailed procedure for DNFB and acetone painting, and behavior observation performed in (H). DH, dorsal horn. Scale bars, 200 μm (C, D) and
100 μm (E, F).
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and DNFB-induced itch responses
The MEK inhibitor U0126, which inhibits the phospho-
rylation of ERK1/2 without affecting p38, JNK, or other
MAP kinase pathway components [26], was used tostudy whether ERK activation is required for itch re-
sponses at the spinal level. U0126 (0.1 μg and 1 μg) was
administered intrathecally [27] 10 min prior to intrader-
mal pruritogen injection. We found that histamine-
induced scratching behaviors were markedly inhibited
Figure 5 Specific expression of pERK in the superficial spinal neurons in histamine-injected and repeated DNFB-painted mice. (A, B)
The vast majority of pERK-positive cells are located dorsally to the PKCγ-positive cells in histamine-inject mice. (C-E) pERK expression co-localizes
with NeuN (arrowheads in C), but not with GFAP (D) or OX42 (E) in mice injected with histamine. (F-H) Laser confocal images show co-localization of
NeuN and pERK (arrowheads in F), but no co-localization of pERK with GFAP (G) or Ox42 (H) in the spinal dorsal horn of repeated DNFB-painted mice.
I, lamina I; IIi, inner lamina II; IIo, outer lamina II; III, lamina III. Scale bars, 100 μm (A, B,) and 50 μm (C-H).
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(Figure 6A, B), but those induced by chloroquine
remained unchanged (Figure 6F). Western blot data
showed that the phosphorylation of ERK1/2 was in-
deed increased after the histamine injection, and it
could be suppressed by the intrathecal application of
U0126 (Figure 6G). In addition, intrathecal injection
of U0126 10 min prior to the last DNFB application
also dramatically inhibited the scratching response in
repeatedly DNFB-treated mice (Figure 6D).
In order to know whether the ERK activation is in-
volved in the maintenance of histamine-induced scrat-
ching response, the U0126 (1 μg) was intrathecallyinjected 10 min after histamine injection. Since the scrat-
ching has fully developed at 10 min post-histamine
injection (Figure 6A), we chose this time point to ex-
plore this possibility. It showed that U0126 dramatic-
ally decreased the number of scratches 10 min after
histamine injection (Figure 6C). Similar results were
obtained in repeatedly DNFB-painted mice, as shown
by an obvious reduction of scratching number when
U0126 was applied 20 min after the last painting of
DNFB (Figure 6E). These results indicate that ERK
activation in the spinal cord is required for both of
the initiation and maintenance of histamine- and DNFB-
induced itch.
Figure 6 Blocking ERK activation with U0126 attenuates the scratching behaviors induced by histamine and DNFB but not chloroquine.
(A, B) The number of scratches induced by histamine treatment (500 μg) is dramatically reduced by intrathecal administration of U0126 10 min before
histamine injection (A, B). The number of scratches in every 5 min is shown (A) and the total number in 30 min period is shown (B). (C) The number
of scratches induced by histamine treatment (500 μg) is dramatically reduced by intrathecal administration of U0126 10 min after histamine injection.
(D, E) A similar effect by U0126 is also observed in repeated DNFB-painted mice. (F) Compared with controls, the number of scratches induced by
chloroquine treatment (200 μg) is unchanged after intrathecal injection of U0126. In each group, at least 5 mice were used (A-F). (G) Western blot
shows the pERK expression in the spinal cord is increased in histamine-treated mice, but this increase was suppressed by the intrathecal administration
of U0126. n = 3 for each group. One way ANOVA, for A, B, D, F, G; P < 0.01 in A, B, D, G; Student’s t-test for C and E; * P < 0.05; **P < 0.01).
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ERK activation
Histamine receptor 1 (H1) antagonists are widely used to
alleviate allergic reactions and provide itch relief [2,28].
To establish whether histamine- and DNFB-induced ERK
activation is mediated by the H1 receptor, its antagonist
chlorpheniramine (10 mg/kg) was administered intraperi-
toneally 20 min prior to histamine injection or final DNFB
application, and mice were sacrificed for pERK immuno-
staining after the 30-min itch response observation. Chlor-
pheniramine but not PBS treatment dramatically reduced
histamine-induced scratching and ERK activation in the
spinal cord (Figure 7A, B). On the other hand, neither
DNFB-induced scratching nor pERK expression were af-
fected by chlorpheniramine (Figure 7C, D), demonstrating
that H1 receptor activation is not involved in DNFB-
induced itch and spinal ERK activation.Because chlorpheniramine (10 mg/kg) was adminis-
tered intraperitoneally, and it may have sedative effects
leading to reduced scratching in histamine-treated mice.
We thus performed the following experiments. Open
field test showed that application of chlorpheniramine in
histamine-treated mice did not affect spontaneous lo-
comotion activity (total traveled distance and velocity:
1385.53 ± 48.23 cm and 5.73 ± 0.83 cm/s in PBS group,
respectively; 1273.36 ± 69.57 cm and 7.01 ± 0.91 cm/s
in chlorpheniramine group, respectively. n = 5 for each;
Student’s t-test, P > 0.05). Von Frey (withdraw threshold:
2.08 ± 0.23 g in PBS group and 2.23 ± 0.29 g in chlor-
pheniramine group, n = 5 for each; Student’s t-test, P >
0.05) and tail immersion tests (tail reflection latency at
48°C, 50°C and 52°C: 8.63 ± 0.40 s, 4.77 ± 0.16 s and
3.65 ± 0.23 s in PBS group; 8.58 ± 0.45 s, 5.03 ± 0.12 s
and 3.45 ± 0.08 s in chlorpheniramine group, respectively.
Figure 7 Chlorpheniramine, an H1 antagonist, inhibits the scratching response and pERK expression induced by histamine but not
DNFB. (A, B) The numbers of scratches (A) and pERK-positive cells in the dorsal horn (B) induced by histamine injection are both significantly
reduced after intraperitoneal administration of chlorpheniramine (10 mg/kg). (C, D) The number of scratches (C) and pERK-positive cells (D) induced
by repeatedly painting DNFB remain unchanged in mice receiving the same chlorpheniramine treatment. Chlorph, chlorpheniramine. n = 6 for each
group. Student’s t-test; *P < 0.05; **P < 0.01.
Zhang et al. Molecular Brain 2014, 7:25 Page 9 of 15
http://www.molecularbrain.com/content/7/1/25n = 5 for each; Student’s t-test, P > 0.05) showed that
mechanical and thermal sensation were not changed
compared with controls treated with PBS. Thus, it is
unlikely that the reduction of scratching behaviors in
histamine-treated mice is caused by the sedative ef-
fects of chlorpheniramine.
Blocking activation of ERK inhibits enhanced neuronal
activation induced by histamine and DNFB
To explore possible neurophysiological basis for ERK ac-
tivation in itch sensation at the spinal level, patch-clamp
recording was conducted in spinal slices prepared from
histamine-, chloroquine- and DNFB-treated mice. We
found that the frequency but not the amplitude of the
spontaneous EPSC of spinal layer IIo neurons was signifi-
cantly increased in histamine-, chloroquine- and DNFB-
treated mice relative to controls (Figure 8A, B), suggesting
more glutamate releasing in the central terminal of DRG
neuron upon itch stimuli. In addition, the threshold
of action potential was dramatically decreased and cor-
respondingly frequency of action potential initiated by
depolarizing current (40 pA, 400 μs) was significantlyincreased in the spinal dorsal horn neuron of histamine-,
chloroquine- and DNFB-treated mice compared with
PBS-treated controls (Figure 8C-E), suggesting that the
excitability of spinal neurons is increased in these mice
received itch-related sensory stimuli. Importantly, the
enhanced excitability of spinal neurons was largely sup-
pressed by bathing of U0126 in mice treated with his-
tamine and DNFB, but not chloroquine (Figure 8C-E).
Noted that neither the action potential threshold nor
evoked action potential frequency from control mice re-
ceiving injection of PBS was changed by bath application
of U0126 (Figure 8C, D). These results suggest that the ac-
tivation of ERK is only involved in the elevation of spinal
neuron excitability in histamine- and DNFB-treated mice
but not those treated with chloroquine.Discussion
A large body of evidence has demonstrated that in-
creased expression of pERK, a well-established indicator
of ERK signaling activation, is involved in pain proces-
sing in the spinal cord [13,18,19,29-31]. In this study, we
Figure 8 Histamine- and DNFB-, but not chloroquine-induced high excitability of spinal dorsal horn neurons is suppressed by U0126.
Spinal slices were prepared 30 min after injection of PBS (20 μl), histamine (100 μg in 20 μl PBS), or chloroquine (80 μg in 20 μl PBS) into hind
paw, or the last painting of DNFB on hind paw. (A, B) Voltage-clamp recording from outer laminar II neurons shows that the frequency but not
the amplitude of sEPSC is increased in mice treated with histamine, chloroquine or DNFB. Six mice were used in each set of experiment, and
recorded neuron numbers are shown in (B). One way ANOVA, P < 0.01; **P < 0.01. (C, D) Current-clamp recording shows the decreased threshold
of action potential (C) and increased frequency of action potential triggered by current injection (D) in histamine-, chloroquine- and DNFB-
treated mice. Bath application of U0126 (1 μM) only prevents the changes in histamine- and DNFB-treated mice but not those treated with
chloroquine. Five mice were used in each experiment and recorded neuron numbers are shown in (C, D). Student’s t-test, *P < 0.05. (E) Samples
of action potential frequency changes after bath application of U0126 in control mice and histamine-injected mice. AP, action potential.
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quired for itch sensation at the spinal level.
As mentioned above, ERK staining has been attributed
to pain [13,20]. In this study, different doses of hista-
mine (50–500 μg) were used to induce scratching res-
ponse. However, it could be argued that the observed
phosphorylation of ERK with high dose of histamine
(e.g. 500 μg) administered at the nape region is due to
histamine-produced nociceptive input rather than itch
sensation. In addition, the rostral back injection of cap-
saicin also generates scratching behavior, although in-
jection of capsaicin is usually considered to produce
nociceptive sensations [23]. To further clarify these is-
sues, itch cheek model was used, because itch and no-
ciceptive responses can be represented by two distinct
behaviors, scratching and wiping [23]. In histamine-
injected mice, the scratching behavior, the indicator of
itch, increased as the dose of histamine increased from
10 to 50 μg, while the wiping behavior, the indicator of
nociception, was kept in a very low level and did not
changed as the dose increased. In addition, pERK ex-
pression was found in the medullary dorsal horn, and
pERK-positive cells were also increased as the dose ofhistamine increased. These results further support the
idea that ERK signaling is activated by histamine-induced
itch sensory input, although the nociceptive input-evoked
spinal ERK activation could not fully excluded.
Acute itch is classified into histamine- and non-
histamine-dependent categories, according to sensitivity
to antihistamine treatment, suggesting that the mole-
cular mechanisms underlying each category differ from
one another [16,17]. A recent study demonstrated that
the G-protein-coupled receptor MrgprA3 specifically me-
diates chloroquine-induced itch in DRG neurons, as evi-
denced by the finding that MrgprA3 mutant mice exhibit
an overall reduction in scratching behaviors induced by
chloroquine, but not histamine [7]. In vivo evidence also
showed that histamine and cowhage (non-histamine prur-
itogen) activate distinct spinal dorsal horn neurons [32].
In this study, we reported herein that ERK signaling in the
spinal dorsal horn is activated in response to histamine-
but not chloroquine-induced acute itch. The observed
lack of pERK expression in the chloroquine-treated mice
is not due to any inability of the spinal neurons to
respond to peripheral itch-related sensory inputs, because
c-Fos expression levels and patterns in the spinal cord in
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Importantly, the specific MEK inhibitor U0126, attenuates
histamine-induced itch responses as well as pERK expres-
sion in the spinal cord, thus confirming the specific role of
ERK activation in histamine-induced acute itch.
What is the neurophysiological basis for ERK signals
in itch sensation at the spinal level? ERK activation in
the spinal dorsal horn only occurs in response to stimuli
that are strong enough to cause C-fibers to fire [13], and
histamine treatment can activate mechanically insensi-
tive C-fibers [33]. Our results showed that the frequency
of spontaneous EPSC of spinal dorsal horn neurons
is increased, and the threshold of action potential is
decreased leading to the increase of action potential
frequency trigged by current injection in histamine-,
chloroquine- and DNFB-treated mice. Based on these
findings, we speculate that itch sensory input may elicit
more glutamate releasing from the central terminal of pri-
mary sensory neurons thereby enhancing the excitability
of spinal neurons. Our results also suggest that the intra-
cellular ERK signaling pathway is involved in the elevation
of spinal neuron excitability in histamine- and DNFB-
induced but not chloroquine-induced itch, because the
suppressive effect by bath application of U0126 was only
observed in the mice treated with histamine and DNFB.
However, there are some technical limitations in our
patch-clamp recording. First, the recording was performed
in spinal slices, and this in vitro condition may not fully
reflect the nature of neuronal physiological property upon
itch-related stimuli in vivo. Second, the timing difference
among itch response, ERK activation and physiological
recording may be an important factor affecting the out-
come of patch-clamp recording. For example, histamine-
induced itch responses are reduced 30 min and pERK
activation is lowered 1 h, while the recording was per-
formed at least 1.5 h after the injection of histamine due
to the time spent in preparing the spinal slices. Thus, our
recording may not truly reveal itch-induced physiological
alteration of spinal neurons because it may change over
time. In vivo recording is needed to further clarify this
issue.
Chronic itch is a common symptom of several chronic
diseases of the skin and other systems, such as atopic
dermatitis and liver or kidney dysfunctions. This type of
itch does not respond to treatment with anti-histamines
and is therefore believed to be mediated by distinct mo-
lecular mechanisms [2,34]. In an attempt to elucidate
some of these mechanisms, repeatedly applying DNFB
to the skin was used, because it causes atopic dermatitis-
like pathological alterations and vigorous scratching be-
haviors in mice [1]. Our data revealed that ERK signaling
is activated in the spinal dorsal horn 30 min after the
last painting of DNFB and that U0126 is able to suppress
the scratching behaviors and enhanced excitability ofspinal neurons induced by DNFB. However, a recent
study reported that pERK-positive cells was not observed
in the spinal cord 1 d after the last DNFB treatment,
and intrathecal injection of U0126 did not affect itch re-
sponse in DNFB-induced chronic itch in mice [35]. This
may reflect the possibility that DNFB-induced phospho-
rylation of ERK is a transient event, but it triggers a
long-lasting central plasticity leading to chronic itch re-
sponse. They failed to reveal suppressive effect of U0126
in DNFB-treated mice may be due to different mouse
strains used and experimental operations. As there is no
effective treatment for chronic itch, ERK pathway may
be a potential target for the development of new itch-
relieving drugs. DNFB-induced itch last for at least one
week after the last painting of DNFB, and more efforts
should be paid in this time window for exploring the
role of ERK signaling in chronic itch. In addition, our
data also showed that the scratching behavior was ob-
served in mice painted with one-time DNFB, suggesting
that DNFB may be able to ignite the sensory fiber which
transmits itch sensation.
A vast number of studies have conclusively shown that
histamine-induced acute itch is mediated by the H1 re-
ceptor, which is the primary target for antihistamine
treatment. Consistently, we found that blocking the H1
receptor with its antagonist chlorpheniramine effectively
suppressed the scratching behaviors induced by histamine
treatment. We also found that histamine-induced ERK ac-
tivation is mediated by the H1 receptor, as illustrated by
the finding that chlorpheniramine treatment significantly
reduced pERK expression in histamine-treated mice.
However, although chlorpheniramine dramatically de-
creased the scratching behavior, it only induced half
reduction of ERK activation responded to histamine.
We only tested this effect at one time point (20 min
before histamine injection), and this may not be the
most suitable time window to fully prevent ERK acti-
vation, and it is also likely that remaining ERK activa-
tion is caused by histamine-induced nociception that
cannot be blocked by chlorpheniramine.
Chlorpheniramine has a sedative effect [36,37], which
may contribute to the suppression of the scratching be-
haviors induced by histamine. However, the spontaneous
locomotion, and mechanical and thermal sensations in
chlorpheniramine-treated mice were not different from
PBS-treated controls, suggesting the suppressive effect
on histamine-induced itch response is less likely caused
by the sedative effect of chlorpheniramine. This is also
supported by the data that chlorpheniramine has no ef-
fect on scratching response in DNFB-treated mice. In
DNFB-treated mice, neither of these suppression effects
by chlorpheniramine was observed, indicating that the
H1 receptor is not involved in DNFB-induced itch and
spinal ERK activation, which is consistent with the clinical
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naling pathway mediates DNFB-induced itch responses
and ERK activation at the spinal level.
Itch and pain, although they share some similarities,
are distinguished by unique behavioral responses [23],
and believed to be mediated by distinct neural circuits
[6]. In an rat model of neuropathic pain, spinal ERK
activation is observed in neurons, astrocytes and micro-
glia throughout the dorsal horn [31]. In contrast, in
histamine-induced acute and DNFB-induced itch models
used in the present study, pERK expression was res-
tricted to spinal neurons primarily located in the super-
ficial dorsal horn. Together, these findings support the
idea that pain and itch are processed by different neur-
onal circuits in the spinal cord [16,17].
Conclusions
Our data provide the first direct line of evidence that
spinal ERK activation is involved in both histamine-
dependent acute itch and DNFB-induced itch. Unlike
histamine-induced itch, DNFB-induced itch and ERK ac-
tivation is not mediated by the H1 receptor at the spinal
level. The central role of ERK phosphorylation in spinal
itch processing provides novel insight into the molecular
mechanisms that govern itch generation and responses,
from which novel anti-itch therapies may be developed.
Materials and methods
Animals
A total of 300 male adult ICR mice (25-35 g) were used.
Animal care procedures were reviewed and approved by
the Animal Study Committee at Tongji University School
of Medicine, Shanghai, China.
Drugs and administration
All pruritogens were purchased from Sigma-Aldich (St.
Louis, MO). Histamine (H7125; 500 μg), chloroquine
(C6628; 200 μg), compound 48/80 (C2313; 100 μg) and
proteinase-activated receptor 2 agonist SLIGRL-NH2
(S9317; 100 μg) were dissolved in 50 μl of 0.01 M phos-
phate buffered saline (PBS; pH7.4) and injected intrader-
mally into the nape to generate acute itch responses
[5,6]. In addition, histamine (200 μg in 20 μl PBS) was
also injected intraplantarly into the hind paw on one
side, in order to explore the topographical expression of
pERK in the spinal cord. To induce itch responses in the
facial region (itch cheek model), histamine (10–50 μg)
dissolved in 10 μl of PBS was injected intradermally into
the cheek region as reported previously [22,23]. It should
be noted that the mice were not anesthetized during the
injection of pruritogens as described previously [23]. To
exclude the possibility that pERK is elicited by scratch
stimuli rather than histamine, pERK expression was alsoexamined in sodium pentobarbital-anesthetized mice
(40 mg/kg body weight, i.p.) that did not scratch.
To induce atopic dermatitis, 150 μl of 0.15% DNFB
(D1529; Sigma-Aldich) in acetone was repeatedly applied
to the shaved skin of the nape [1,24]. DNFB was applied
twice in the first week and once per week for the next
two weeks, for a total of four applications. Control mice
were administered the same treatment, but either pain-
ted with four times of acetone alone or with 3 times of
acetone first and one time of DNFB last on the day be-
havioral observation commenced.
The MEK inhibitor U0126 [1,4-diamino-2,3-dicyano-
1,4-bis (oaminophenylmercapto) butadiene] (U120; Sigma-
Aldich) was dissolved in dimethyl sulfoxide (DMSO) to
create a 100X stock solution, which was stored at −80°C
and diluted in PBS prior to use. U0126 (0.1 μg and 1 μg in
10 μl PBS) was administered intrathecally with a 30 gauge
needle at the lumbar level, as described previously [39],
10 min prior to pruritogen injection or final DNFB applica-
tion. In order to explore if ERK activation is also involved
in the maintenance of itch response, U0126 was also
applied 10 min after histamine intradermal injection or
20 min after the last painting of DNFB. Control mice re-
ceived an intrathecal injection of the same volume of 1%
DMSO in PBS.
The histamine H1 receptor antagonist chlorpheniramine
(C3025; Sigma-Aldich; 10 mg/kg; dissolved in PBS) was
administered intraperitoneally 20 min prior to pruritogen
injection or final DNFB application. Control mice received
an equal volume of PBS only.
Behavior study
Itch response evaluation was performed as described
previously [5,23]. For acute itch, mice were habituated
to ambient conditions for 30 min and then injected in-
tradermally in the nape or cheek with one of the prurito-
gens mentioned above. Hind paw scratching behaviors
directed towards injection site were recorded for 30 min
immediately following the injection. In DNFB-treated
mice, scratching behaviors were evaluated in the same
way starting at 10 min after the last application. For
some experiments, the scratching behavior was recorded
uninterruptedly for 6 h immediately after and for 2 h
one week after the last painting of DNFB.
The following behavioral observation was used to exa-
mine whether chlorpheniramine used in our study show
sedative effects, as this may affect scratching response
induced by histamine and DNFB. For the open field test,
the mice were put into the center of the open chamber
(42 cm wide × 42 cm high × 42 cm long) 20 min after in-
traperitoneal injection of chlorpheniramine (10 mg/kg).
Mice injected with PBS were used as control. The cham-
ber was thoroughly cleaned up with 75% ethanol between
tests. During the 30-min test session, the total distance
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corders and analyzed with ehtoVision XT8 (Noldus Infor-
mation Technology, Wageningen, Netherlands). For the
von Frey test, mice were put on the elevated wire grid for
habituation for 2 h and the plantar surface of the hind
paw was stimulated with calibrated von Frey monofila-
ments. The 50% paw withdrawal threshold for the von
Frey assay was determined using Dixon’s up-down me-
thod [40]. For the tail immersion test, mice were gently
restrained in a black cloth pocket which the mice volun-
tarily entered. The protruding one third of the tail was
then dipped into the water at 48°C, 50°C and 52°C, re-
spectively, with 15 min interval. Latency to respond to the
heat stimuli with vigorous flexion of the tail was measured
three times and averaged. In all behavioral tests, the be-
havioral observer was blind to experimental designs.
Immunohistochemical and histological analyses
Mice were deeply anesthetized with sodium pentobar-
bital and perfused through the ascending aorta with PBS
followed by 4% paraformaldehyde in 0.1 M phosphate
buffer (pH 7.4). After the perfusion, spinal cord and
DNFB-treated nape skin were removed and post-fixed
overnight. For mice received injection of pruritogens in
the nape region, cervical cord segments (C4-C8) were
removed; for those received injection of histamine in the
hind paw, lumbar cord segments (L4-L5) were removed;
for those received the injection in cheek region, the cau-
dal hindbrain was removed.
Samples were cut transversely into 30 μm-thick frozen
sections on a cryostat. Every sixth section was collected
as one set and they were processed for immunofluo-
rescence. The following primary antibodies: rabbit anti-
pERK1/2 antibody (1:600; Cell Signaling Technology,
Danvers, MA), rabbit anti-c-Fos antibody (1;1000; Santa
Cruz Biotechnology Inc, Santa Cruz, CA), mouse anti-
NeuN antibody (1:1000; Millipore, Temecula, CA), mouse
anti-OX42 antibody (1:500; Serotec, Oxford, UK) and
mouse anti-GFAP antibody (1:1000; Millipore). Sections
were incubated with the primary antibodies overnight
at 4°C, and then with Cy3- (1:500, Jackson Immuno-
Research, West Grove, PA) or Alexa Fluor 488-conjugated
species-specific secondary antibodies (1:500; Invitrogen,
Carlsbad, CA) for 2 h at room temperature. For double
immunofluorescence, sections were incubated with a mix-
ture of rabbit polyclonal and mouse monoclonal primary
antibodies, followed by a mixture of Alexa Fluor 488- and
Cy3-conjugated anti-rabbit and anti-mouse IgG. In ad-
dition, hematoxylin/eosin staining was performed on sec-
tions of DNFB- and acetone-treated skin to identify any
pathological alterations.
For pERK and PKCγ co-immunostaining (both are
rabbit polyclonal antibodies), we employed the tyra-
mide signal amplification system (TSA Plus Biotin Kit,PerkinElmer, Waltham, MA) [41,42]. Spinal cord sections
were first incubated overnight at 4°C with rabbit anti-
pERK antibody (1:15000), a dilution at which no im-
munoreactivity for pERK could be detected by the
conventional staining procedure. Sections were then
incubated with HRP-labeled goat anti-rabbit IgG (1:100;
KangChen, Shanghai, China) for 3 h and TSA Biotin
Amplification Reagent (1:50; PerkinElmer) for 10 min at
room temperature. Signals were visualized with Cy3-
conjugated streptavidin (1:500; PerkinElmer). After being
washed in PBS, sections were incubated with the second
primary antibody, rabbit anti-PKCγ antibody (1:1000;
Santa Cruz Biotechnology), overnight at 4°C, and then
with Alexa Fluor 488-conjugated donkey anti-rabbit
IgG (1:500; Invitrogen) for 3 h at room temperature.
The stained sections were observed under a Nikon
fluorescence microscopy equipped with a Nikon Coolpix
digital camera (DS-Ri1; Tokyo, Japan) or laser confocal
microscopy (TCS SP5 II; Leica, Germany). For counting
pERK-positive cells in the cervical, lumbar and medul-
lary dorsal horns, all immunostained sections in the one
set of sections were included. A cell was considered to
be pERK positive when signal/noise ratio (intensity of
immunofluorescence in cell body vs background) was > 2.
All images were made into figures using Adobe Photoshop
(Adobe Systems Incorporated, San Jose, CA) and only
minor adjustments to the contrast and brightness settings
were applied if necessary.
Western blot
To confirm the suppressive effects of intrathecal U0126
on spinal phosphorylation of ERK, we performed Western
blot in mice received histamine (500 μg) injection at
the nape region. U0126 (1 μg) was applied 10 min before
the injection, and cervical cord segments were removed
10 min after the injection. They were homogenized
in the T-PER Tissue Protein Extraction Reagent with
10% v/v Halt™ proteinase and phosphatase inhibitor
cocktail (Thermol Scientific, Amarillo, TX). After a
centrifugation of 12000 rpm for 15 min at 4°C, the super-
natant was collected, boiled with protein loading buffer in
95°C for 5 min and subjected to SDS-PAGE electrophor-
esis. The cellulose nitrate membrane contained the target
protein was incubated with the pERK primary antibody
(1:1000; Cell Signaling Technology) overnight in 4°C, with
the horseradish peroxidase-conjugated secondary antibody
for 1.5 h at room temperature, and visualized with the
Luminata™ Crescendo western HRP substrate purchased
from Millipore (Billerica, MA).
Spinal slice preparation
Mice (4–6 week old) received intraplantar injection of
histamine (100 μg in 20 μl PBS), chloroquine (80 μg in
20 μl PBS) or PBS (20 μl) were used. For DNFB-treated
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as mentioned earlier. The lumbar spinal cord (L4-L5)
was removed from the mice under urethane anesthesia
as reported previously [43-45]. Spinal segment was placed
in a shallow groove formed in an agar block and glued
to the bottom of the microslicer stage. Transverse slices
(600 μm) were cut on a vibrating microslicer. The slices
were perfused with Kreb’s solution (3 ml/min) saturated
with 95% O2 and 5% CO2 at 36 ± 1°C for 1–2 h prior
to experiment. The Krebs solution contains (in mM):
NaCl 117, KCl 3.6, CaCl2 2.5, MgCl2 1.2, NaH2PO4 1.2,
NaHCO3 25 and glucose 11.
Patch clamp recordings in spinal slices
The whole cell patch-clamp recordings were made from
outer lamina II neurons in voltage and current mode.
Patch pipettes were fabricated from thin-walled, borosili-
cate, glass-capillary tubing (1.5 mm o.d., World Preci-
sion Instruments, Sarasota, FL). After establishing the
whole-cell configuration, neurons were held at −70 mV
for recording sEPSC in voltage clamp mode or action
potential in current clamp mode, respectively. The re-
sistance of a typical patch pipette was 5–10 MΩ. The in-
ternal solution contains (in mM): potassium gluconate
135, KCl 5, CaCl2 0.5, MgCl2 2, EGTA 5, HEPES 5 and
ATP-Mg 5. The signals were amplified with an Axopatch
700B amplifier (Molecular Devices, Sunnyvale, CA) and
filtered at 2 kHz and digitized at 5 kHz. All data were
stored with a personal computer using pCLAMP 10
software and analyzed with Mini Analysis 6.0 program
(Synaptosoft, Decatur, GA) and Clampfit.
Quantification and statistics
Data are expressed as mean ± SEM. Differences between
two groups were compared using 2-tailed Student’s t-
test. One way ANOVA followed by a Fisher post hoc test
to evaluate the differences among multiple groups. Two
way repeated ANOVA was used for comparison of data
from the mice with repeatedly painting of DNFB or acet-
one, because these measurements were collected in the
same mice at different time points, as shown in Figure 4H.
The regression analysis was used to expression the
correlation of the ERK activation and the number of
scratches. All the data were analyzed using OriginPro 8.5
(OriginLab, Northampton, MA). The criterion for statis-
tical significance was P < 0.05.
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